Genomic Vision Expands Its Services Offering to Fulfill the Demands For DNA Replication Analysis for Drug Discovery in Cancer Treatment
22 Luglio 2021 - 6:00PM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) (the “Company” -
FR0011799907 – GV), a biotechnology company that develops tools
and services dedicated to the analysis and control of changes in
the genome, today announced that it has expanded its EasyComb
services in the field of drug discovery driven by the healthcare
market need to develop novel and specific drugs to stop cancer
growth.
During the past ten years, the proprietary replication combing
assay (RCA) has become a standard tool for understanding the
function and mechanism of drugs used in cancer treatment. Genomic
Vision has partnered and contributed to this field with key
academic institutions worldwide to ensure successful adoption of
its technology resulting in many high impact scientific
publications.
One recent example is the study published in the journal
Molecular Cell‡ (Cong et al., 2021) by the University of
Massachusetts Medical School which used RCA to analyze the
replication gaps in BRCA1 to determine the sensitivity of poly
(ADP-ribose) polymerase inhibition (PARPi), a new class of
potential drug targets.
“Our findings establish a model to help further develop targeted
treatment with PARPi, such that combined therapies maximize exposed
lagging strand gaps,” said Sharon Candor, PhD, University of
Massachusetts Medical School.
Genomic Vision has experienced significant increase in demand
for replication analysis in the past few months from globally
recognized leaders in the pharma and biotech segments. These
companies are investigating novel drugs for inhibition of the
growth of cancer cells by surveying recombination and replication
fork kinetics. This has enabled the expansion of Genomic Vision’s
services and will allow the company to take a leadership position
in providing tools and services in the specific analysis of DNA
replication in drug discovery.
“Based on the significant amount of replication analysis data
accumulated over the past years, we are now expanding our services
to include an end-to-end approach, including enhancement of our
analysis pipeline that includes artificial intelligence-based
detection. This will allow the pharmaceutical and biotechnology
industries to use RCA data as a unique tool in finding new classes
of drugs for cancer treatment,” said Dominique Remy-Renou, CEO of
Genomic Vision.
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Genomic Vision, based near Paris in Bagneux, is a
public listed company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on February 9, 2021 under
reference number R.21-002, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210722005468/en/
Genomic Vision Dominique Remy-Renou CEO Tel.: +33 1 49 08
07 51 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Grafico Azioni Genomic Vision (EU:GV)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Genomic Vision (EU:GV)
Storico
Da Mag 2023 a Mag 2024